LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

Publication | Closed Access

DOI

Citations

References

2021

Year

G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris, Yoon Sim Yap, Gabe S. Sonke, L. Hart, M. Campone, Katarína Petráková, Eric P. Winer, W Janni,

Annals of Oncology

Endocrine OncologyBreast OncologyPhase Iii Monaleesa-2MedicineGynecologyLba17 Overall SurvivalBreast CancerCancer TreatmentOncologyRadiation OncologyMammary Gland DevelopmentEndocrine-related Cancer